Apolipoprotein News and Research

RSS

Stopping metformin early linked to higher dementia risk in older adults with type 2 diabetes

Early termination of metformin treatment in older adults with type 2 diabetes is associated with a higher risk of dementia, according to a cohort study. The research has significant implications for diabetes management, especially among those at higher risk for dementia.

29 Oct 2023

Boosting brain health with iron and manganese: A dietary defense against cognitive decline

The recent study published in Nutrients explores the link between dietary mineral intake and cognitive impairment in elderly Spanish individuals, finding that increased consumption of iron and manganese significantly reduced cognitive impairment risk in women but showed no effect in men.

25 Oct 2023

Is COVID-19 a risk factor for Alzheimer's disease?

The study explores the interconnected risks between COVID-19 and Alzheimer's Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.

23 Oct 2023

Saliva test breakthrough: Early detection for ectopic pregnancies on the horizon

Salivary proteins may offer early detection for ectopic pregnancies, potentially saving maternal lives through a non-invasive diagnostic approach. The study identifies specific proteins that are prominently present in ruptured ectopic pregnancy cases, highlighting the potential for developing a saliva-based diagnostic kit.

9 Oct 2023

Study discovers protective genetic mutation for kidney disease

African Americans have long been known to be at increased risk of kidney disease due to a dangerous genetic mutation that creates a hole in the kidney cells, but Vanderbilt University Medical Center (VUMC) researchers have now discovered a protective genetic mutation that covers the hole to eliminate the risk.

6 Oct 2023

Breakthrough antibody therapy targets Alzheimer's risk gene, offers hope for effective treatment

Researchers introduced and characterized a novel platform based on monoclonal antibodies (mAbs).

6 Oct 2023

Microglial states and their impact on Alzheimer's disease

Researchers examined 152,459 microglial transcriptomes from 443 individuals, identifying 12 transcriptional states and their relationship to Alzheimer's disease.

3 Oct 2023

Identification of Alzheimer's disease-associated micro-RNA biomarkers through network-based analysis

Micro-ribonucleic acids (miRNAs) linked to cognition and Alzheimer's disease (AD).

3 Oct 2023

Novel vaccine lowers LDL cholesterol independent of statins

The effectiveness of virus-like particle (VLP)-based vaccines targeting epitopes in the low-density lipoprotein (LDL) receptor.

2 Oct 2023

Vascular risk factors influence cognitive health differently in men and women with Alzheimer's disease

Researchers utilize imaging findings to elucidate how Alzheimer's dementia can present considerable variations depending on the sex of the individual.

27 Sep 2023

How does the APOE4 gene play both hero and villain in your health risks?

The study reveals that APOE4, a genetic risk factor for Alzheimer's Disease and cardiovascular diseases, has complex effects on mortality risk. While APOE4 carriers with higher AD neuropathology have increased mortality risk, those with low neuropathology had a reduced risk of certain cancers, warranting further research into this genetic factor's diverse impact on health outcomes.

14 Sep 2023

Could your daily routine lead to dementia? New research points to sedentary lifestyle as potential risk factor

In a recent study, researchers investigated whether accelerometer-assessed sedentary behavior was associated with incident dementia.

13 Sep 2023

Unlocking the future of dementia: Your telomere length could predict your risk

The recent study in General Psychiatry found that leukocyte telomere length (LTL) is significantly associated with the risk of developing dementia, especially Alzheimer's disease. Using data from over 430,000 individuals, the study suggests that telomere length could serve as a predictive biomarker for brain health and dementia risk.

12 Sep 2023

Scientists develop new method to detect key fat-filled particles in the brain

Scientists have created a method to detect key fat-filled particles known as lipoproteins in the central nervous system, opening a new view into the workings of the brain.

12 Sep 2023

The role of exercise-induced hormone irisin in amyloid beta reduction

Researchers explored the biological mechanisms by which exercise-induced irisin attenuates amyloid-beta pathology in Alzheimer’s disease.

8 Sep 2023

Breakthrough genome-wide study uncovers new loci impacting apolipoprotein E levels and Alzheimer's risk

New genetic factors that affect the plasma apolipoprotein E levels.

8 Sep 2023

New biomarker could help identify people at risk for vascular dementia

Dementia is a group of brain diseases that share similar symptoms, such as memory, language, orientation, and behavioral issues. Vascular dementia generally develops in the elderly, affecting between 1% and 4% of people over the age of 65, according to Alzheimer's Switzerland.

4 Sep 2023

Scientists discover new role for liver tPA in regulating cholesterol levels

Despite advances in treatment for high cholesterol, heart disease remains the leading cause of death in the U.S. Scientists at the Medical College of Wisconsin (MCW) are investigating the role of a form of cholesterol called very-low-density lipoprotein – and their findings may lead to new treatment options in the future.

1 Sep 2023

Higher educational attainment may have a protective effect against Alzheimer's in people with genetic risk

A new study by researchers from Mass General Brigham further illustrates that when it comes to risk of Alzheimer's disease, even genetically determined forms of the disease, genetics is only one piece of the puzzle.

30 Aug 2023

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.